Company / Gross Profit
TEVA PHARMACEUTICAL INDUSTRIES LTD Gross Profit History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$8.9B
FY2025
5-year range
$7.0B / $8.9B
FY2021-FY2025
Trend
+10.8%
vs FY2024
Sector context
#2 of 29
Health Care
What the data says
Among 29 Health Care companies, TEVA PHARMACEUTICAL INDUSTRIES LTD is in the top 7% for gross profit. Gross Profit has increased for 3 consecutive years, from $7.0B in FY2022 to $8.9B in FY2025.
Based on SEC 10-K filings.
$8.9B in FY2025 with a 5-year CAGR of +3.0%. Ranks 2nd among 29 companies in Health Care.
Improved from $7.6B to $8.9B over the past 2 years.
Health Care sector context is included.
Gross Profit over time
Growth rates
- 3-Year CAGR
- +8.6%
- 5-Year CAGR
- +3.0%
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 29This company $8.9B Sector average $3.5B
▼
+158.2% above sector average
Key checks
Key Insights
- TEVA PHARMACEUTICAL INDUSTRIES LTD's gross profit has grown for 3 consecutive years.
- 5-year CAGR of +3.0%, indicating consistent growth.
- In FY2025, gross profit increased 10.8% year-over-year.
- Ranks #2 out of 29 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -9.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.9B | +10.8% |
| FY2024 | $8.1B | +5.5% |
| FY2023 | $7.6B | +9.6% |
| FY2022 | $7.0B | -8.2% |
| FY2021 | $7.6B | -1.7% |
| FY2020 | $7.7B | +2.5% |
| FY2019 | $7.5B | -9.1% |
| FY2018 | $8.3B | -21.8% |
| FY2017 | $10.6B | -8.9% |
| FY2016 | $11.7B | +2.6% |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026